



**Elizabeth Ferrill:**

Elizabeth Ferrill is a partner in the Washington DC office of Finnegan LLP. *Intellectual Asset Management Patent 1000* has described her as an “undisputed expert on design patents” who is “always updated and enlightening others with her deep knowledge,” “very involved in the design bar,” and “gives her clients an outstanding service.” She focuses her practice on all aspects of design patents, including litigation through jury trial, appeal, counseling, post-grant, and prosecution. She currently serves as the leader of the firm’s Electrical Practice Group. Prior to joining the firm, Beth served as a judicial law clerk to the Honorable Liam O’Grady at the U.S. District Court for the E.D. of Virginia, Alexandria Division. She has a JD with honors from the University of North Carolina-Chapel Hill, a M.S. in Computer Science from the Georgia Institute of Technology, and a B.S. in Computer Science and Distinguish Graduate with academic and military distinction from the United States Air Force Academy.

Beth litigates design patent and trade dress matters in U.S. district courts. In addition, she has appeared before the U.S. International Trade Commission, the U.S. Court of Appeals for the Federal Circuit, and the U.S. Court of Appeals for the Fourth Circuit. She counsels clients who hold design patents as well as those accused of infringement. She has experience with design patents related to consumer and industrial products, graphical user interfaces and icons, and more. She has prosecuted families of design patents before the U.S. Patent and Trademark Office (USPTO), directed prosecution in foreign countries, and argued appeals and post-grant proceedings in design cases before the Patent Trial and Appeal Board. She has a special interest in strategic counseling related to acquiring for worldwide protection for designs.



**Jennifer Rea Deneault:**

Jenna has been recognized for her talent and dynamism. She was named as a 2025 Lawdragon 500 Leading Lawyers in America. In September 2024, LMG Life Sciences awarded Jenna the US Rising Star – Intellectual Property award. In October 2024, she was included in Benchmark Litigation's 40 & Under List, which identified the “best and brightest litigators across the US.” In September 2023, she received the Rising Star award from the New York Law Journal, which “celebrates those attorneys who are making a difference in their field in the early stages of their careers and already leaving their marks.” Jenna was also recognized in the 2023 and 2024 Lawdragon 500 X – The Next Generation, which recognizes lawyers “who have taken the industry by storm in recent years.”

Jenna is an active leader in the New York and intellectual property legal communities. She is a Board Member and Co-Chair of the Membership Committee for the New York Intellectual Property Law Association. In May 2024, she received the Volunteer of The Year award from NYIPLA for her contributions to the organization. Jenna is also vice chair of the Patent Litigation Committee for the Federal Circuit Bar Association. Some of her recent presentation topics include ethics in patent cases, Section 112 in ANDA and BPCIA cases, the Federal Circuit Rules of Practice, and the Patent Trial and Appeal Board (PTAB).

Beyond trial experience, Jenna’s time in court includes serving as a law clerk for the Honorable Robert W. Schroeder III in the U.S. District Court for the Eastern District of Texas, and as a judicial fellow for then-U.S. District Court Judge Leonard P. Stark and U.S. Magistrate Judge Christopher J. Burke in the U.S. District Court for the District of Delaware. Jenna also interned for the Honorable Randall R. Radar and the Honorable Pauline Newman at the U.S. Court of Appeals for the Federal Circuit, the Honorable Susan G. Braden at the U.S. Court of Federal Claims, and the Honorable Theodore R. Essex at the U.S. International Trade Commission. In

addition, while in law school, Jenna worked as a Patent Examiner at the U.S. Patent & Trademark Office where she focused on battery and fuel cell applications.



**Andrew Roper:**

Andrew Roper is a partner in Haug Partners' New York offices. The majority of his practice focuses on patent litigation. Additionally, he performs due diligences, and evaluations of IP assets. Mr. Roper also regularly works on appellate matters before the Federal Circuit.



**Annie Bolton:**

Annie Bolton is an associate in the New York office of Haug Partners, where she focuses on pharmaceutical patent and intellectual property litigation. Annie graduated from Fordham University School of Law, where she served as the Symposium Editor for the Urban Law Journal. During law school, Annie spent a semester working in the Legislative and Policy Advocacy Clinic and worked as a research assistant for the Neuroscience and Law Center.

Prior to attending law school, Annie spent four years working as a biological researcher at Teva Pharmaceuticals, where she developed bioassays for analytical development and quality control testing.

Annie graduated with a B.S in Chemistry and Psychology from the University of Miami, where she performed neuroscience research using functional MRI to study resting state functional connectivity in HIV-positive participants.



## Preston K. Ratliff II

Partner, Litigation Department

prestonratliff@paulhastings.com

**Preston K. Ratliff II** is a partner in the firm's Litigation practice in New York. Mr. Ratliff focuses his practice on complex, high-stakes litigation with an emphasis on patent litigation in the biotechnology, pharmaceutical, chemical, agricultural, and renewable fuel sectors. He has successfully represented major and emerging companies both pre-trial and at trial. *Chambers USA* notes that Mr. Ratliff is "really outstanding and excels at all aspects of litigation. What stands out is that he is a brilliant strategist who sees the big picture and can anticipate risks that aren't always necessarily apparent...he is a very calming and unflappable presence even in the most difficult and stressful situations."

Mr. Ratliff also has extensive experience counseling clients with respect to their IP portfolios and evaluating strategic licensing opportunities. In addition, Mr. Ratliff is a frequent publisher in patent journals and an invited speaker at some of the most prestigious life sciences industry conferences.

### Recent Representations

- ***Seagen Inc. v. Daiichi Sankyo Company Limited.***

Lead counsel in a hotly-contested, multi-billion dollar breach of contract intellectual property biotechnology dispute involving antibody-drug conjugates ("ADCs") for the treatment of various cancers. Mr. Ratliff, along with his team, obtained a complete victory dismissing the opposition's claims as both substantively meritless and time-barred. This win was reported to be among the largest disputes ever handled by the International Centre for

### New York

T: 1(212) 318-6055

F: 1(212) 230-7742

### Practice Areas

Litigation

Patent Office

Patent Litigation

Intellectual Property

Life Sciences and Healthcare

Global Dispute Resolution

Practice for Japanese Clients

### Languages

English

### Admissions

United States Patent &  
Trademark Office

New York Bar

### Education

American University

Washington College of Law,

J.D. 1999

Syracuse University, B.S.  
1996

Dispute Resolution, which is the American Arbitration Association's forum for global conflict resolution.

- ***Sumitomo Dainippon Pharma et al. v. Emcure Pharmaceuticals et al.***

Lead counsel that locked in full patent protection and revenues arising from Sumitomo Dainippon Pharma's chemical compound patent for its billion-dollar-plus-per-year schizophrenia and bipolar drug, Latuda®. Specifically, Mr. Ratliff obtained a Federal Circuit decision that affirmed a district court's November 2016 claim construction ruling and a February 2017 judgment of infringement against three generic drug manufacturers. Taken together, these dual victories secured patent protection for Latuda® while blocking more than a dozen generic drug manufacturers, including industry giant Teva Pharmaceuticals, from launching competing products.

- ***Merck Sharp & Dohme Corp. v. Sandoz Inc. and Accord Healthcare, Inc.***

Co-led a trial team that won an important trial victory for Merck concerning its pharmaceutical product Emend® for Injection, which is used in the prevention of nausea and vomiting associated with cancer chemotherapy. After a bench trial, the district court ruled that Merck's patent was valid and infringed, defeating the challenge brought by several generic companies. Mr. Ratliff also co-led a team that convinced the Patent Office to deny Canadian pharmaceutical company Apotex's petition for an IPR, challenging a patent protecting Merck's Emend® for Injection franchise. Mr. Ratliff also convinced the PTAB to deny Apotex's further request to rehear its IPR petition.

- ***Pfizer Inc. v. Amgen Fremont Inc. and Amgen Inc.***

Co-led a team that obtained a complete victory in a highly-complex breach of contract and intellectual property dispute in Delaware Chancery Court concerning billion-dollar biotechnology drug products.

- ***Sucampo Pharmaceuticals Inc. et al. v. Par Pharmaceuticals, Inc. et al.***

Lead trial counsel for Sucampo in a Hatch-Waxman litigation protecting its leading medication Amitiza® for bowel disorders. In its suit against Par, Mr. Ratliff helped secure a settlement that provides Sucampo additional market exclusivity, as well as a royalty-bearing

- ***Biovail International Laboratories v. Andrx Pharmaceuticals, LLC et al.***

Co-led a trial team that secured a highly-favorable settlement in a patent infringement litigation regarding the company's top-selling drug product for managing blood pressure.

## **Involved**

- Intellectual Property Owners Association
- New Jersey Intellectual Property Law Association
- Metropolitan Black Bar Association
- Admitted to practice in various courts throughout the United States, including the United States Court of Appeals for the Federal Circuit
- Registered to practice before the United States Patent and Trademark Office

## **Accolades and Recognitions**

- *Chambers USA*, Intellectual Property: Patent (2022-2024)
- *IAM Patent 1000*, Leading Patent Practitioner (2015-2025)
- In addition, IAM noted that he “has prevailed at trial for major companies in hard-fought battles”; as testament to his leadership qualities and outstanding legal dexterity, he assumed the chairmanship of the New York Litigation practice.
- *LMG Life Sciences*, *Life Sciences Star* (2018-2023)
- *Managing Intellectual Property*, IP Stars (2019-2025)
- Managing IP New York Litigator of the Year Finalist 2024
- Minority Corporate Counsel Association Rainmakers Award 2024
- The American Lawyer's Litigator of the Week Runner-Up 2024
- Topped *Law360*'s “Legal Lions” list for his Federal Circuit victory securing patent exclusivity against multiple defendants

concerning Sunovion's billion-dollar blockbuster schizophrenia and bipolar drug, Latuda®

- Selected as one IAM Strategy 300's "World's Leading IP Strategists"
- Named a "Minority Powerbroker" by *Law360*
- Named one of *Law360*'s five "Rising Stars" for Intellectual Property

## **Education**

- American University Washington College of Law, J.D. (1999)
- Syracuse University, B.S. in Chemical Engineering and minor in German Language (1996)

## **News**

### **April 12th, 2024**

Paul Hastings Recognized by The American Lawyer for Victory in Multi-Billion Dollar International Life Sciences Dispute

### **July 14th, 2023**

Paul Hastings Recognized in Managing IP's 2023 Edition of IP Stars

### **July 13th, 2023**

Paul Hastings Again Recognized in the 2023 Edition of IAM Patent 1000

### **July 6th, 2022**

2022 IAM Patent 1000 Ranks More Than 20 Paul Hastings' Intellectual Property Lawyers Across Seven Jurisdictions

### **June 15th, 2022**

Managing IP Magazine Illuminates Paul Hastings' Intellectual Property Practice with 16 Lawyers Recognized as 'IP Star'

## **Events**

### **April 19th, 2023**

ACI's 18th Annual Paragraph IV Disputes Conference